Background: Expression of cytokines and growth factors have been shown to be highly correlated with the prognosis in esophageal squamous cell carcinoma (ESCC), a dead disease with poor prognosis. The suppressor of cytokine signaling (SOCS) family of proteins are key factors in the feedback system that regulates the expression of cytokines and growth factors in cells. Yet the role of the SOCS family of proteins in ESCC is hardly known. Method: We analyzed the prognostic effects of 16 single nucleotide polymorphisms (SNPs) within the SOCS family of genes in 632 ESCC patients using MassARRAY system. The underlying mechanisms of SOCS SNPs effect on prognosis was analyzed using luciferase assay. The possible functions of SOCS5 in ESCC cells were analyzed by transiently over-expression. Result: We repeatedly observed that the 3 SNPs in SOCS5, SOCS5:rs3814039, SOCS5:rs3738890, and SOCS5: rs3768720, were significantly correlated with both overall (OS) and progression-free survival (PFS) of ESCC patients (rs3814039, p¼0.032 for OS and p¼0.009 for PFS; rs3738890, p¼0.016 for OS, and p¼0.008 for PFS; rs3768720, p¼0.005 for OS and p¼0.002 for PFS). SOCS5: rs3768720 was also significantly associated with distant metastasis (Ptrend¼0.028). The luciferase assay revealed that SOCS5:rs3814039 and SOCS5: rs3738890 might influence the prognosis by regulating SOCS5 expression. Functional analysis demonstrated SOCS5 was able to regulate epidermal growth factor receptor (EGFR) expression and migration activity of ESCC cells. Conclusion: Our study demonstrates the roles of SOCS5 in ESCC prognosis. The genetic polymorphisms of SOCS5 could serve as a novel therapeutic biomarker for improving the prognosis of ESCC.
P1.14-23 Thymoma: An Epidemiological and Clinico-Pathological Profile in Nepalese Population S. Acharya 1 R. Pun 2 1 Clinical Oncology, National Academy of Medical Sciences, Bir Hospital, Kathmandu/NP, 2 Clinical Oncolgy, Nepal Medical College and Teaching Hospital, Kathmandu/NP Background: Thymomas and thymic carcinomas are most common tumor of anterior mediastinum representing 0.5 % to 1.5% of all the malignancies. Surgery is the main stay of treatment with adjuvant radiation recommended for the invasive thymomas. It accounts for 0.1% of all the malignancies as per National Cancer Registry Nepal. Because of the rarity of the tumor we aim to review the profile of patient with thymic tumor in our patient population. Method: All the patient with diagnosis of thymoma attending the Department of Clinical oncology, National Academy of Medical Sciences (NAMS), Bir Hospital, Nepal during 2009 -2015 was evaluated. We reviewed the record of all registered, histologically diagnosed thymoma and thymic carcinomas and are presented in this study. Result: Total of 51 record with thymoma and thymic carcinomas were reviewed out of which 71% (36) patient were male. The mean age was 46.99 years with youngest being 18 years and the eldest 70 years of age. Most common presenting symptom was shortness of breath (37%), followed by cough (23%0, generalized weakness (14%), dysphagia (14%) and drooping of eyelid (12%). About 29.41% of patient was diagnosed with myasthenia gravis. 14% of patients were diagnosed on stage II, 57% on stage III and 29% with stage IV (modified Masaoka clinical stage). WHO pathological stage B 39% (20) [(B1-12%(6), B2-18%(9), B3-10%(5)] was most common, with A 24%(12), AB 20%(10), and C 18%(9). 11% of patient underwent upfront surgery. Neoadjuvant therapy was offered for 63%(32) with 68.75%(22) resectability rate. 27% were eligible only for palliative treatment. About 95% patient received chemotherapy and 90.19% patient received radiation therapy either curative or palliative. 62.74% received curative radiation. 62.74% (32) patients are still on regular follow up with no signs of relapse. Conclusion: Multimodality therapy remains the main stay of treatment for thymomas rendering the disease curative. Significant number of patient received neoadjuvant chemotherapy therapy followed by surgery and adjuvant radiation therapy. WHO Type B seems to be more frequent type. Thymoma is quite often associated with myasthenia gravis without adverse effect on prognosis. However, in view of limited study due to rarity of the disease various aspects yet to be explored. Keywords: Multimodality treatment, thymic carcinoma, thymoma P1.14-24 External Radiotherapy Concurrent with Cisplatin Plus 5-Flurouracil in Locally Advanced Carcinoma of Esophagus R. Pun, 1 S. Acharya 2 1 Clinical Oncolgy, Nepal Medical College and Teaching Hospital, Kathmandu/NP,, 2 Clinical Oncology, National Academy of Medical Sciences, Bir Hospital, Kathmandu/NP Background: Esophageal cancer is the eighth most common cancer in the world with the high rates of local recurrence and metastasis. As per the data of National Cancer Registry Nepal it ranks among the top ten cancers with 2.6% prevalence. Definitive concurrent chemo radiotherapy (CCRT) is the standard for the non surgery patients, and the use of Cisplatin with 5-Flurouracil is the common chemotherapy regimen. Method: A prospective and comparative study was undertaken from 2014-2015 to evaluate the effect of CCRT in patients with locally advanced carcinoma of esophagus in our patient population.The eligibilty criteria included locally advanced, ECOG score of <2. Patients received chemo radiotherapy (50Gy / 25fractions) and Cisplatin 75mg/m2 on Day 1 and 5-Flurouracil 1000mg/m2 on Day 1-Day 4 every 4 weeks apart on weeks 1 and 5. Radiation only group received 64 Gy/33 fractions. Result: 40 patients were enrolled in the study. Among these patients 65.0% were male and the disease was prevalent at 55-64 years age group. 72.5% of the patients were smokers, 55.0% were alcohol consumers and 20.0% were Tobacco chewers. The most common site of the primary tumor was the mid thoracic region of the esophgus consisting of 62.5%. The combined modality of treatment was toxic but managable with supportive care. Thre were 4 drop outs, 1 from CCRT group and 3 from Radiation (RT) alone group due to the progression of the disease. 65.0% attained partial response and 25.0% achieved complete response in the CCRT group which was in favor of CCRT in comarison to the RTalone group. Conclusion: Concurrent chemoradiotherapy
